Abstract
Inhibitors in patients with hemophilia are a rare complication of a rare disease causing pain and disability in patients and impairment to the quality of their lives. Recent advances in treatment have brought improvements, but they have done so by absorbing larger amounts of financial resources. This study involved 52 Italian patients with hemophilia with high-responding inhibitors who were longitudinally observed for 18 months to evaluate concomitantly cost of care and quality of life. Overall, 0.6 bleeding episodes per patient per month were recorded. This frequency of events was lower than that reported in other cohorts of patients with hemophilia who were not taking inhibitors. The average monthly cost of care was, in euros, €18 000 (US $18 000) per patient, mainly because of treatment products. Recombinant activated factor VII, mostly used for orthopedic surgery, represented 50% of the expenses. Quality of life, measured through validated questionnaires, was similar to that of patients with severe hemophilia without inhibitors. In particular, physical quality of life was similar to that in patients with diabetes and on dialysis, whereas mental quality of life was comparable to that in the general population. This study shows that hemophilia complicated by inhibitors, a prototype of rare disease, requires high amounts of resources for management that provides a satisfactory quality of life.
| Original language | English |
|---|---|
| Pages (from-to) | 2358-2363 |
| Number of pages | 6 |
| Journal | Blood |
| Volume | 102 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Oct 1 2003 |
Fingerprint
ASJC Scopus subject areas
- Hematology
Cite this
Cost of care and quality of life for patients with hemophilia complicated by inhibitors : The COCIS study group. / Gringeri, Alessandro; Mantovani, Lorenzo G.; Scalone, Luciana; Mannucci, Pier Mannuccio.
In: Blood, Vol. 102, No. 7, 01.10.2003, p. 2358-2363.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cost of care and quality of life for patients with hemophilia complicated by inhibitors
T2 - The COCIS study group
AU - Gringeri, Alessandro
AU - Mantovani, Lorenzo G.
AU - Scalone, Luciana
AU - Mannucci, Pier Mannuccio
PY - 2003/10/1
Y1 - 2003/10/1
N2 - Inhibitors in patients with hemophilia are a rare complication of a rare disease causing pain and disability in patients and impairment to the quality of their lives. Recent advances in treatment have brought improvements, but they have done so by absorbing larger amounts of financial resources. This study involved 52 Italian patients with hemophilia with high-responding inhibitors who were longitudinally observed for 18 months to evaluate concomitantly cost of care and quality of life. Overall, 0.6 bleeding episodes per patient per month were recorded. This frequency of events was lower than that reported in other cohorts of patients with hemophilia who were not taking inhibitors. The average monthly cost of care was, in euros, €18 000 (US $18 000) per patient, mainly because of treatment products. Recombinant activated factor VII, mostly used for orthopedic surgery, represented 50% of the expenses. Quality of life, measured through validated questionnaires, was similar to that of patients with severe hemophilia without inhibitors. In particular, physical quality of life was similar to that in patients with diabetes and on dialysis, whereas mental quality of life was comparable to that in the general population. This study shows that hemophilia complicated by inhibitors, a prototype of rare disease, requires high amounts of resources for management that provides a satisfactory quality of life.
AB - Inhibitors in patients with hemophilia are a rare complication of a rare disease causing pain and disability in patients and impairment to the quality of their lives. Recent advances in treatment have brought improvements, but they have done so by absorbing larger amounts of financial resources. This study involved 52 Italian patients with hemophilia with high-responding inhibitors who were longitudinally observed for 18 months to evaluate concomitantly cost of care and quality of life. Overall, 0.6 bleeding episodes per patient per month were recorded. This frequency of events was lower than that reported in other cohorts of patients with hemophilia who were not taking inhibitors. The average monthly cost of care was, in euros, €18 000 (US $18 000) per patient, mainly because of treatment products. Recombinant activated factor VII, mostly used for orthopedic surgery, represented 50% of the expenses. Quality of life, measured through validated questionnaires, was similar to that of patients with severe hemophilia without inhibitors. In particular, physical quality of life was similar to that in patients with diabetes and on dialysis, whereas mental quality of life was comparable to that in the general population. This study shows that hemophilia complicated by inhibitors, a prototype of rare disease, requires high amounts of resources for management that provides a satisfactory quality of life.
UR - http://www.scopus.com/inward/record.url?scp=0141482007&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0141482007&partnerID=8YFLogxK
U2 - 10.1182/blood-2003-03-0941
DO - 10.1182/blood-2003-03-0941
M3 - Article
C2 - 12816859
AN - SCOPUS:0141482007
VL - 102
SP - 2358
EP - 2363
JO - Blood
JF - Blood
SN - 0006-4971
IS - 7
ER -